支气管哮喘诊断及半胱氨酰白三烯受体拮抗剂治疗的研究进展  

Research progress in diagnosis of bronchial asthma and treatment with cysteinyl leukotriene receptor antagonist

作　　者：高雅文 徐芳 姜鲁宁[2] Gao Yawen;Xu Fang;Jiang Luning(Clinical Medicine, Jining Medical University, Jining 272013, China;Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China)

机构地区：[1]济宁医学院临床医学院,272013 [2]济宁医学院附属医院呼吸与危重症医学科,272029

出　　处：《中华诊断学电子杂志》2021年第1期67-70,共4页Chinese Journal of Diagnostics(Electronic Edition)

基　　金：山东省中医药科技发展计划项目(2017-274);山东省中医药科技发展计划项目(2019-0466)。

摘　　要：支气管哮喘(简称哮喘)是一种气道慢性炎症性疾病,主要特征是可逆性气道阻塞和气道高反应。哮喘是高度异质性疾病,具有不同的潜在疾病过程,其诊断主要取决于病史和体格检查,部分类型哮喘症状不明显,容易造成漏诊、误诊。半胱氨酰白三烯(CysLTs)是细胞运输和免疫反应的重要介质,在哮喘发病中发挥重要作用,CysLTs受体拮抗剂可单独用于控制哮喘症状。笔者就哮喘诊断及CysLTs受体拮抗剂在哮喘治疗方面的进展作一综述。Bronchial asthma(asthma)is a chronic inflammatory disease of the airway,which is mainly characterized by reversible airway obstruction and airway hyperresponsiveness.Asthma is a highly heterogeneous disease with different underlying disease processes.Its diagnosis mainly depends on medical history and physical examination.Some types of asthma symptoms are not obvious,which can easily lead to missed diagnosis and misdiagnosis.Cysteinyl leukotrienes(CysLTs)are important mediators of cell transport and immune response,and play an important role in the pathogenesis of asthma.CysLTs receptor antagonists can be used alone to control asthma symptoms.This article reviews the progress in asthma diagnosis and treatment of asthma with CysLTs receptor antagonists.

关 键 词：哮喘 诊断 半胱氨酰白三烯受体 拮抗剂 

分 类 号：R56[医药卫生—呼吸系统]